arq 736
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2010 (NCT01225536)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
BRAF inhibitor
- Serine/threonine-protein kinase RAFINHIBITOR
RAF1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]- Mol. weight
- 674.54 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Prodrug
Sources
- ChEMBLCHEMBL5314407 ↗
- ChEMBLCHEMBL3545296 ↗
Also known as
- arq 736
- arq 736
- arq-736
- arq-736
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01225536 | Phase 1 | Oct 1, 2010 | ArQule |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ArQule | For profit | 1 | 1 | 1 | 2010 |
1 organizations
Page 1 / 1